AIDX

20/20 Biolabs, Inc.
CAPPED RATING

20/20 Biolabs, Inc. (AIDX) is rated C (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B+); its weakest is Momentum (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C
Value
B
Factor Score 3.4 / 5.0
Growth
B+
Factor Score 3.8 / 5.0
Profitability
C-
Factor Score 2.0 / 5.0
Momentum
F
Factor Score 0.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA 0.0
Rev Growth YoY 36.5%
Gross Margin 31.5%
Price Return 3M -63.5%
Price Return 12M -99.2%
Catalyst Signal 0.00
Market Cap $2.5M
TTM Revenue $2.0M
Price / Sales 1.2
ROE -331.2%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B (3.4) B+ (3.8) C- (2.0) F (0.6) C+ (2.6) C (2.5)
2026-11-10 B- (3.0) B+ (3.8) C- (2.1) D- (0.8) C+ (2.6) C (2.5)
2026-11-03 B- (3.0) B+ (3.8) C (2.2) D- (0.9) C+ (2.7) C+ (2.5)
2026-10-27 B- (3.0) B+ (3.8) C- (2.1) D- (0.7) C+ (2.6) C (2.5)
2026-10-20 B- (3.0) B+ (3.8) C- (2.1) D- (0.7) C+ (2.6) C (2.5)
Page 1 of 4